Schwab Charles Investment Management Inc. cut its stake in Esperion Therapeutics Inc (NASDAQ:ESPR) by 0.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 90,971 shares of the biopharmaceutical company’s stock after selling 872 shares during the quarter. Schwab Charles Investment Management Inc. owned approximately 0.35% of Esperion Therapeutics worth $5,990,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently modified their holdings of ESPR. Caisse DE Depot ET Placement DU Quebec acquired a new position in shares of Esperion Therapeutics in the third quarter valued at about $12,583,000. BNP Paribas Arbitrage SA grew its stake in shares of Esperion Therapeutics by 12,603.4% in the third quarter. BNP Paribas Arbitrage SA now owns 201,476 shares of the biopharmaceutical company’s stock valued at $10,098,000 after acquiring an additional 199,890 shares in the last quarter. Amundi Pioneer Asset Management Inc. acquired a new position in shares of Esperion Therapeutics in the third quarter valued at about $9,517,000. MUFG Securities EMEA plc acquired a new position in shares of Esperion Therapeutics in the third quarter valued at about $9,022,000. Finally, Columbus Circle Investors acquired a new position in shares of Esperion Therapeutics in the third quarter valued at about $2,606,000. 91.69% of the stock is currently owned by institutional investors.
Several research firms recently commented on ESPR. Needham & Company LLC upgraded shares of Esperion Therapeutics from a “buy” rating to a “strong-buy” rating and upped their price target for the company from $72.00 to $81.00 in a research note on Thursday, December 14th. JPMorgan Chase & Co. restated a “neutral” rating and issued a $65.00 price target (up from $55.00) on shares of Esperion Therapeutics in a research note on Wednesday, February 21st. ValuEngine upgraded shares of Esperion Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Deutsche Bank upped their price target on shares of Esperion Therapeutics to $100.00 and gave the company a “buy” rating in a research note on Friday. Finally, BidaskClub downgraded shares of Esperion Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday. Seven investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $87.36.
Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings data on Tuesday, February 20th. The biopharmaceutical company reported ($1.44) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.80) by $0.36. During the same quarter last year, the company earned ($1.29) EPS. research analysts anticipate that Esperion Therapeutics Inc will post -5.66 earnings per share for the current year.
In other Esperion Therapeutics news, Director Nicole Vitullo sold 11,674 shares of the stock in a transaction dated Thursday, January 25th. The shares were sold at an average price of $71.79, for a total transaction of $838,076.46. Following the sale, the director now directly owns 3,177 shares in the company, valued at $228,076.83. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 32.50% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This news story was posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another website, it was stolen and republished in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.americanbankingnews.com/2018/03/13/esperion-therapeutics-inc-espr-shares-sold-by-schwab-charles-investment-management-inc.html.
About Esperion Therapeutics
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.